|

C402-CD19-CAR Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Shanghai Exuma Biotechnology Ltd.1

Indications

  • HGBL, Nos1
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements1
  • PMBL1
  • Follicular Lymphoma Grade 3B1
  • DLBCL, Nos Genetic Subtypes1

Other1 trial

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.